
In a shock move, MSD Chairman and Chief Executive Officer Kenneth Frazier (pictured) has announced that he is to resign …

Simon Williams, Head of Communications and Policy at Heart UK, discusses the threat posed by cholesterol in the development of …

NICE has dished out a double judgement turning down two drugs for advanced renal cell carcinoma, a form of kidney …

Japanese pharma giant Takeda has announced that it is to partner up with US-based Shattuck Labs in a collaboration to …

The number of active clinical trials in the cancer space has reached more than 1,000 and rising, outstripping the number …

A report from the Royal College of Paediatrics and Child Health (RCPCH) has highlighted a “hugely disturbing” rise in cases …

The FDA has launched an investigation after five deaths thought to be caused by an obesity treatment surgery in which …

Celgene has announced that it has chosen not to scoop up Sutro Biopharma, rejecting to take advantage of an option …

A team of researchers at Washington University School of Medicine (WUSM) in St Louis and the Eunice Kennedy Shriver National …

Paul Workman, Chief Executive and President of the Institute of Cancer Research, examines the spiralling cost of cancer treatments and …

Another week, another busy week in pharma. The last seven days have seen some remarkable strides in the diabetes space, …

Great news in the cardiovascular space as results from the National Heart Failure Audit indicate that better treatment has led …

Pharmaceutical production has long been the object of scrutiny to ensure the highest levels of quality and safety are maintained. …

In possibly the biggest single biotech investment ever made, Swiss biotech firm Roivant has received a $1.1 billion cash injection …

NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma …